

Declaration for Patent Application

Docket Number: 0652.2200000

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled: Camel, An Alternative Translation Product of the Tumor Antigen Lage-1, the specification of which is attached hereto unless the following box is checked:

- ☒ was filed as PCT International Application Number PCT/EP99/07832; international filing date of October 15, 1999 (filed April 16, 2001 under 35 U.S.C. § 371 as U.S. Application No. 09/807,512); and was amended on April 16, 2001 (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56, including for continuation-in-part applications, material information that became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or (f), or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application, which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or PCT international application having a filing date before that of the application on which priority is claimed.

Send Correspondence to:



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:


(202) 371-2600

Appl. No. 09/807,512
Docket No. 0652.2200000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	<u>100</u>	<u>Peter I. SCHRIER</u>	
Signature of sole or first inventor			Date 22-1-2002
Residence	<u>Leiden, Netherlands</u>		<u>NLX</u>
Citizenship	<u>Netherlands</u>		
Mailing Address	<u>Schelpenkade 17, NL-2313 ZT Leiden, NL</u>		
<hr/>			
Full name of second inventor	<u>200</u>	<u>Corlien A. AARNOUDSE</u>	
Signature of second inventor			Date 22-1-2002
Residence	<u>Katwijk, Netherlands</u>		<u>NLX</u>
Citizenship	<u>Netherlands</u>		
Mailing Address	<u>Pr. Alexanderlaan 18, NL-2224 XM Katwijk, Netherlands</u>		
<hr/>			
Full name of third inventor	<u>300</u>	<u>Karl-Heinz HEIDER</u>	
Signature of third inventor			Date 26.02.2002
Residence	<u>Stockerau, Austria</u>		<u>ATX</u>
Citizenship	<u>German</u>		
Mailing Address	<u>Johann-Strauss-Promenade 4/11, A-2000 Stockerau, Austria</u>		
<hr/>			

Appl. No. 09/807,512
Docket No. 0652.2200000

Full name of fourth inventor	<u>400</u>	<u>Christoph KLADE</u>
Signature of fourth inventor	 March 15, 2002	
Residence	<u>Wiener Neustadt, Austria</u> 	
Citizenship	<u>Austria</u>	
Mailing Address	Gröhrmühlgasse 1b/17, A-2700 Wr. Neustadt, Austria	

P:\USERS\Schwartz\Cases\0652\2200000\Declaration

Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Schriger et al.

Application No./Patent No.: 09/807,512 Filed/Issue Date: April 16, 2001,

which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999.

Entitled: Camel, An Alternative Translation Product of the Tumor Antigen LAGE-1

University Hospital Leiden, a university
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest, or
2. an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. An Assignment from the inventors of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel To be filed, Frame To be filed, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (*i.e.*, the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: X March 14, 2002

Name: X Carbo, HG

Title: X managing director div. ~

Signature: X Carbo

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Peter I. Schrier, and (2) Corlien A. Aarnoudse, the undersigned inventors hereby sell and assign to University Hospital Leiden (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) for the United States of America (as defined in 35 U.S.C. § 100),
 and throughout the world,

(a) in the invention known as Camel, An Alternative Translation Product of the Tumor Antigen Lage-1 for which application for patent in the United States of America has (have) been executed by the undersigned on (1) 01/22/02, and (2) 01/22/02 (also known as United States Application No. 09/807,512, filed April 16, 2001, which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999) in any and all applications thereon, in any and all Letters Patent therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NO FEE RECORDATION

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 22-1-2002

Signature of Inventor:


(1) Peter I. Schrier

Date: 22-1-2002

Signature of Inventor:


(2) Corlien A. Aarnoudse

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

University Hospital Leiden, a university of The Netherlands, having a principal place of business at Rijnsburgerweg 10, Leiden, NL-2321 RP, Netherlands, is the Assignee of an undivided part interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee from (1) Peter I. Schrier and (2) Corlien A. Aarnoudse executed on (1) 01/22/02 and (2) 01/22/02 of an invention known as Camel, An Alternative Translation Product and of the Tumor Antigen Lage-1 (Attorney Docket No. 0652.2200000/EKS/ALS), which is disclosed and claimed in a patent application of the same title by the inventors Peter I. Schrier, Corlien A. Aarnoudse, Karl-Heinz Heider, and Christoph Klade (said application filed on April 16, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/807,512, which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999).

*Done
Reg. No.
36,759
4/8/02*

The Assignee hereby appoints the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Esq., Registration No. 25,688; Jorge A. Goldstein, Esq., Registration No. 29,021; David K.S. Cornwell, Esq., Registration No. 31,944; Robert W. Esmond, Esq., Registration No. 32,893; Tracy-Gene G. Durkin, Esq., Registration No. 32,831; Michele A. Cimbala, Esq., Registration No. 33,851; Michael B. Ray, Esq., Registration No. 33,997; Robert E. Sokohl, Esq., Registration No. 36,013; Eric K. Steffe, Esq., Registration No. 36,688; Michael Q. Lee, Esq., Registration No. 35,239; Steven R. Ludwig, Esq., Registration No. 36,203; John M. Covert, Esq., Registration No. 38,759; Linda E. Alcorn, Esq., Registration No. 39,588; Lawrence B. Bugaisky, Esq., Registration No. 35,086; Donald J. Featherstone, Esq., Registration No. 33,876; and Robert C. Millonig, Esq., Registration No. 34,395. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Boehringer Ingelheim International GmbH as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: University Hospital Leiden
SIGNATURE: X *Werk*
BY: X *Carlo HG*
TITLE: X *managing director*
DATE: X *March 14, 2002*

POWER OF ATTORNEY FROM ASSIGNEE

Boehringer Ingelheim International GmbH, a corporation of Germany, having a principal place of business at Binger Straße 173, D-55216 Ingelheim am Rhein, Germany, is an assignee of an undivided part interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee from 1) Karl-Heinz Heider and 2) Christoph Klade executed on (1) 02/26/02 and (2) 03/15/02, of an invention known as Camel, An Alternative Translation Product of the Tumor Antigen Lage-1 (Attorney Docket No. 0652.2200000/EKS/ALS), which is disclosed and claimed in a patent application of the same title by the inventors Peter I. Schrier, Corlien A. Aarnoudse, Karl-Heinz Heider, and Christoph Klade (said application filed on April 16, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/807,512, which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999).

The Assignee hereby appoint the U.S. attorneys associated with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR:	<u>Boehringer Ingelheim International GmbH</u>
SIGNATURE:	<u>ppa</u> <u>Pluia</u> <u>h. hof</u>
BY:	<u>X</u> <u>Dr. Dieter LAUDIEN</u> <u>Marion HOSS</u>
TITLE:	<u>X</u> <u>Head of Patent Division</u> <u>Authorised person of Patent Division</u>
DATE:	<u>X</u> <u>March 18, 2002</u>

Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Schrier et al.

Application No./Patent No.: 09/807,512 Filed/Issue Date: April 16, 2001,

which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999.

Entitled: Camel, An Alternative Translation Product of the Tumor Antigen LAGE-1

Boehringer Ingelheim International GmbH, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. the assignee of the entire right, title, and interest, or
2. an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. An Assignment from the inventors of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel To be filed, Frame To be filed, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: March 18, 2002

Name: X Dr. Dieter LAUDIEN

Title: Head of Patent Division

Signature: X Paul

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: (1) Karl-Heinz Heider, and (2) Christoph Klade, the undersigned inventors hereby sell and assign to Boehringer Ingelheim International GmbH (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) for the United States of America (as defined in 35 U.S.C. § 100),
 and throughout the world,

(a) in the invention known as Camel, An Alternative Translation Product of the Tumor Antigen Lage-1 for which application for patent in the United States of America has been executed by the undersigned on (1)02/26/02 and (2)03/15/02 (also known as United States Application No. 09/807,512, filed April 16, 2001, which is the U.S. national phase of PCT/EP99/07832, international filing date October 15, 1999) in any and all applications thereon, in any and all Letters Patent therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE,KESSLER,GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: 26.02.2002

Signature of Inventor:

Karl-Heinz Heider

(1) Karl-Heinz Heider

Date: March 15, 2002

Signature of Inventor:

Christoph Klade

(2) Christoph Klade

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOTE FOR RECORDATION